Schizophrenia Trial, Recruiting (NCT05704582)

Schizophrenia Trial, Recruiting NCT05704582 Sponsor: Ciusss de L'Est de l'Île de Montréal Condition: Schizophrenia

Printed from Voxsanity (voxsanity.com.au) — NCT05704582 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Schizophrenia

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People aged 18 or older who meet at least 4 of the DSM-5 criteria for Cannabis Use Disorder (a recognised pattern of problematic cannabis use — confirm with trial site for full details)
People who have been diagnosed with schizophrenia, schizoaffective disorder, or bipolar disorder with psychotic symptoms, confirmed through a structured clinical interview

Who may not be able to join:

People who currently have a substance use disorder involving any substance other than cannabis
People who are currently receiving medication or psychological treatment specifically for Cannabis Use Disorder
People who are currently going through a medically supervised cannabis withdrawal (detoxification) program
People who have a neurological disorder (a condition affecting the brain or nervous system)
People who have a serious physical illness that is not currently stable
People who are unable to provide informed consent to participate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 15 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Alexandre Dumais, MD, PhD, University of Montreal, Institut universitaire en santé mentale de Montréal

Phone: 514-251-4000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05704582

Sponsor: Ciusss de L'Est de l'Île de Montréal

Phase: Not Applicable

Status: Recruiting

Condition: Schizophrenia

Trial contact: 514-251-4000

More information: https://clinicaltrials.gov/study/NCT05704582

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People aged 18 or older who meet at least 4 of the DSM-5 criteria for Cannabis Use Disorder (a recognised pattern of problematic cannabis use — confirm with trial site for full details)
People who have been diagnosed with schizophrenia, schizoaffective disorder, or bipolar disorder with psychotic symptoms, confirmed through a structured clinical interview

Who may not be able to join:

People who currently have a substance use disorder involving any substance other than cannabis
People who are currently receiving medication or psychological treatment specifically for Cannabis Use Disorder
People who are currently going through a medically supervised cannabis withdrawal (detoxification) program
People who have a neurological disorder (a condition affecting the brain or nervous system)
People who have a serious physical illness that is not currently stable
People who are unable to provide informed consent to participate

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 15 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Ciusss de L'Est de l'Île de Montréal

Registry

ClinicalTrials.gov

Start date

1 February 2023

Est. completion

1 January 2027

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Change in cannabis use (Timeline Follow-Back)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov